|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72.82 USD | +0.03% |
|
-.--% | +0.96% |
| 05-20 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| 05-15 | Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT | MT |
| Market Cap | 11.3B 9.89B 9.13B 8.52B 16.04B 1,068B 16.33B 110B 42.51B 527B 42.45B 41.5B 1,836B | P/E 2024 |
-10.1x | P/E 2025 | -14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 9.65B 8.45B 7.8B 7.27B 13.7B 912B 13.95B 93.53B 36.31B 450B 36.26B 35.45B 1,569B | EV / Sales 2024 |
181x | EV / Sales 2025 | 492x |
| Free-Float |
96.26% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Avidity Biosciences, Inc.
| 1 day | +0.03% | ||
| 6 months | +0.90% | ||
| Current year | +0.96% |
| Current year | 72 |  | 73.06 |
| 1 year | 27.7 | | 73.06 |
| 3 years | 4.82 | | 73.06 |
| 5 years | 4.82 | | 73.06 |
| 10 years | 4.82 | | 73.06 |
| Manager | Title | Age | Since |
|---|---|---|---|
John McKenna
PSD | President | - | 2026-02-26 |
Eduard Marti
TRE | Treasurer | - | 2026-02-26 |
Jaime S. Huertas
SEC | Corporate Secretary | - | 2026-02-26 |
| Director | Title | Age | Since |
|---|---|---|---|
Jaime S. Huertas
BRD | Director/Board Member | - | 2026-02-26 |
Eduard Marti
BRD | Director/Board Member | - | 2026-02-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02-26 | Issuer sale | Chief Technology Officer | 547,865 | 0.3814% | ||
| 02-26 | Issuer sale | Chief Financial Officer | 721,352 | 0.5021% | ||
| 02-26 | Issuer sale | Chief Technology Officer | 430,990 | 0.3000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | -.--% | +150.84% | +556.63% | 11.3B | |
| -1.27% | +1.03% | +18.93% | -13.10% | 64.28B | |
| -0.57% | +5.82% | +53.94% | +227.66% | 57.29B | |
| -3.94% | +39.10% | +39.10% | +39.10% | 43.45B | |
| -0.56% | +1.65% | -51.04% | -58.77% | 38.02B | |
| +0.03% | +9.83% | +72.45% | -23.97% | 31.98B | |
| +0.16% | +13.90% | +151.83% | -42.81% | 27.66B | |
| -0.63% | +8.95% | +67.03% | +82.72% | 22.91B | |
| -0.56% | +5.64% | +2.91% | +174.96% | 17.74B | |
| -0.13% | -0.94% | +60.31% | +119.58% | 16.45B | |
| Average | -0.78% | +6.42% | +56.63% | +106.20% | 33.11B | |
| Weighted average by Cap. | -1.01% | +5.94% | +44.90% | +69.37% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 10.9M 9.54M 8.8M 8.21M 15.47M 1.03B 15.75M 106M 41M 508M 40.94M 40.03M 1.77B | 18.76M 16.42M 15.15M 14.14M 26.63M 1.77B 27.11M 182M 70.57M 875M 70.46M 68.89M 3.05B |
| Net income | -322M -282M -260M -243M -458M -30.47B -466M -3.12B -1.21B -15.04B -1.21B -1.18B -52.39B | -685M -599M -553M -516M -972M -64.73B -990M -6.64B -2.58B -31.94B -2.57B -2.51B -111B |
| Net Debt | -1.49B -1.31B -1.21B -1.13B -2.12B -141B -2.16B -14.49B -5.62B -69.74B -5.62B -5.49B -243B | -1.65B -1.44B -1.33B -1.24B -2.34B -156B -2.38B -15.97B -6.2B -76.87B -6.19B -6.05B -268B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RNA Stock
Select your edition
All financial news and data tailored to specific country editions
